Article citationsMore>>

S. Moulder, N. Valkov, A. Neuger, J. Choi, J. H. Lee, S. Minton, P. Munster, J. Gump, M. Lacevic, R. Lush and D. Sullivan, "Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response," Cancer, Vol. 113, No. 10, 2008, pp. 2646-2654.

has been cited by the following article:

• TITLE: Active Hexose Correlated Compound (AHCC) Alleviates Gemcitabine-Induced Hematological Toxicity in Non-Tumor-Bearing Mice

  AUTHORS: Daisuke Nakamoto, Kota Shigama, Hiroshi Nishioka, Hajime Fujii

  KEYWORDS: Anticancer Drug; Bone Marrow Suppression; Colony Formation; Hemoglobin; Mushroom Extract; White Blood Cells

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.3 No.5, September 24, 2012

  ABSTRACT: Active hexose correlated compound (AHCC) is known as a dietary supplement derived from an extract of a basidiomycete mushroom. The present study was conducted to evaluate the role of AHCC in alleviating the side effects, particularly hematological toxicity, in non-tumor-bearing mice receiving monotherapy with gemcitabine (GEM). The results from the GEM treatment groups with and without AHCC administration were compared to control group that received vehicle alone. The GEM alone treatment reduced peripheral leukocytes and hemoglobin, and bone marrow cell viability in spite of no influence on body weight, food consumption, and renal and hepatic parameters. Supplementation with AHCC significantly alleviated these side effects. The colony forming assay of bone marrow cells revealed that AHCC improved reduction of colony forming unit-granulocyte macrophage (CFU-GM) and burst forming unit-erythroid (BFU-E) related to GEM administration. However, when mRNA expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) was examined using a quantitative reverse transcription polymerase chain reaction (RT-PCR), AHCC showed no effect for the mRNA levels of their hematopoietic growth factors. These results support the concept that AHCC can be beneficial for cancer patients with GEM treatment through alleviating the hematotoxicity.